|Slideshows|January 11, 2021

7 Questions That Separate ADHD From Bipolar Disorder

What are they key differences between ADHD and bipolar disorder? How can they be identified?

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe

Related Content

Brain Function Biomarker Testing In Psychiatry With Universal Brain EEG

ByKazu Okuda, MD

August 21st 2026

Neuropsychiatry in the News: Wearable Technology for Parkinson Disease, Ecopipam for Tourette Syndrome

ByLeah Kuntz

August 19th 2026

Update on Varenicline for Smoking Cessation in Patients With Bipolar Disorder

ByDavid N. Osser, MD

August 18th 2026

FDA Approves Tauklarify (MK-6240) For Tau Pathology Detection in Alzheimer Disease

ByJessica Walters

August 14th 2026

New Consensus Guidelines Classify Stuttering as a Brain-Based Disorder

ByGerald A. Maguire, MD

August 11th 2026

Latest CME

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Video

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Video

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

Video

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

7 Questions That Separate ADHD From Bipolar Disorder

Related Content

Brain Function Biomarker Testing In Psychiatry With Universal Brain EEG

Neuropsychiatry in the News: Wearable Technology for Parkinson Disease, Ecopipam for Tourette Syndrome

Update on Varenicline for Smoking Cessation in Patients With Bipolar Disorder

FDA Approves Tauklarify (MK-6240) For Tau Pathology Detection in Alzheimer Disease

New Consensus Guidelines Classify Stuttering as a Brain-Based Disorder

Latest CME

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

FDA Feedback Paves Way for New IND Filing for PT00114 in Generalized Anxiety Disorder

A Practical Role for Long-Acting Buprenorphine in Opioid Use Disorder Care

Kratom Component in Clinical Trial for Opioid Use Disorder

Objective Measurement for Psychiatry: Universal Brain's ERP System

Psyched Perspectives: ADHD in Underrecognized Populations, With Paige Walton, MD